Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Jun 25.
Published in final edited form as: Reproduction. 2025 Jan 2;169(1):e240080. doi: 10.1530/REP-24-0080

Contraception Considerations in Transmasculine and Gender Diverse Adolescents & Young Adults

Kirsten Das 1, Veronica Gomez Lobo 1
PMCID: PMC12192487  NIHMSID: NIHMS2056685  PMID: 39418097

Abstract

Contraception care is an important aspect of comprehensive gender affirming care in transmasculine and gender non-binary (TGD) adolescent and young adults (AYA). TGD AYA seek contraception care for a variety of reasons and there are several important considerations that are unique to this population. In addition to pregnancy prevention, transmasculine and gender nonbinary persons may seek contraception to achieve amenorrhea, reduce gender dysphoria, or as part of their gender affirming journey. While patients on testosterone therapy often experience amenorrhea, pregnancy has been reported and testosterone is not a form of contraception. Visits for contraceptive counseling provide an opportunity to discuss fertility goals and preservation planning as well as the possibility that some methods may provide endometrial protection. In this narrative review, we analyze the current literature and discuss specific considerations for contraceptive use in this population. We also propose a contraception overview for shared decision making for patients and their clinicians.

Keywords: Contraception, transgender health, adolescent health, reproductive care, gender affirming care, birth control

In Brief:

Transmasculine and gender diverse adolescents and young adults often can have nuanced considerations when utilizing contraception. This narrative review discusses contraception utilization patterns, specific considerations in this population, and proposes a patient-oriented comparison of contraceptive options.

Introduction

Contraception is an important aspect of comprehensive gender affirming care for transgender and gender diverse adolescents and young adults (AYA) (S. Pradhan, V. Gomez-Lobo, 2019). While these patients may seek contraceptive care for very similar reasons to cisgender persons, there are unique considerations and concerns in this population that providers should understand and consider. Gender refers to a person’s own sense of inner self and gender dysphoria refers to distress caused by feeling that one’s identity does not align with one’s sex at birth. Throughout this narrative review, we will utilize the term transgender and gender diverse (TGD) persons to refer to those whose gender identity is transmasculine, non-binary, or gender diverse and were assigned female sex at birth. There continues to be gaps in research and now increasing limitations placed on clinicians caring for this population.

Gender Affirming Care

Gender care includes affirming one’s sense of gender identity through social, medical, and surgical steps. Each person’s journey is unique and often nonlinear, and the role of the clinician is to support patients in their transition (E. Coleman, A.E. Radix, et al., 2022). Social transition refers to the steps that a person takes to affirm one’s gender identity through gender expression and can occur at varying points in their lives (J.L. Turban, D. King, et al., 2021). Medical transition can include puberty suppression often with gonadotropin releasing hormone agonists (GnRHa) when a young person is Tanner Stage 2 or gender affirming hormone therapy (GAHT or testosterone therapy) (E. Coleman, A.E. Radix, et al., 2022). Surgical transition is a step that some TGD chose to take and for transmasculine patients can include top surgery (e.g., mastectomy), gender affirming hysterectomy, salpingectomy, oophorectomy, or bottom surgery (e.g., metoidioplasty, phalloplasty, or vaginectomy).

Current Contraceptive Use in Transgender and Gender Diverse Adolescent and Young Adults

There is limited prospective data evaluating contraception preferences, continuation rates, and amenorrhea rates in the TGD AYA population; however, several studies have evaluated current and past contraception use in this population. A 2019 cross-sectional survey study of contraceptive use for the purpose of contraception in 150 TGD (mean age of 27), noted that 24% used condoms, 8% intrauterine device (IUD), 2.7% a pill (unspecified type – estrogen and progestin versus progestin only) (B. Stark, J.M. Hughto, 2019). Within this same study, the lifetime use of oral contraceptives was quite high at 50% and lifetime IUD use of 10%. Additionally, qualitative data looking at contraception use in this same population noted that the most common reasons for use were for prevention of sexually transmitted infections and pregnancy. In TGD adults, a 2018 questionnaire study noted that the majority of TGD persons used condoms, combined oral contraceptives (COCs), or progestin only pills (POPs) (A. Light, et al., 2018).

Similar to the cisgender AYA population, pills and condoms are commonly utilized for pregnancy and sexually transmitted infection (STI) prevention respectively and many reported that they preferred external condoms and implants because these methods provided fewer reminders of their natal anatomy and were not perceived as interfering with testosterone use (A. Light, et al., 2018, M. Agénor, et al., 2020). These studies also help illustrate that there is a diverse use of contraception in this population and that there is some acceptability of combined oral contraceptives although lower than in the cisgender female population (K. Hall, et al., 2012).

Several studies on current contraceptive use reveal that a significant number of TGD individuals utilize contraception for the purpose of menstrual suppression in addition to other non-contraceptive methods of menstrual suppression. For example, a 2020 study among young TGD adults (ages 18 to 29) noted that participants chose their contraceptive method mainly for menstrual suppression or addressing their gender dysphoria (M. Agénor, et al., 2020). Another 2023 study of contraception use in over 500 TGD AYA, noted that 24.7% were on menstrual suppression at their initial visit to a gender service specialist. Combined oral contraceptive pills use was the most common method used for menstrual suppression (46.6%), followed by norethindrone (29.8%), and depot medroxyprogesterone (14.5%) (D. Moussaoui, et al., 2023).

Another retrospective cohort study of over 100 TGD AYA at a single gender affirming clinic focusing on menstrual suppression reported that the most utilized methods were norethindrone acetate (70%, a progestin pill that is not a contraceptive method) and the levonorgestrel IUD (20%) (B. Schwartz et al., 2023). Other methods in this study included combined oral contraceptive pill (6%), progestin-only oral contraceptive pill (1%), the etonogestrel implant (1%). The differences in method preference in these studies may reflect provider counseling including comfort with more invasive methods or differences in sub-populations and underlying goals of the patient.

Contraception Counseling in Transgender and Gender Diverse Adolescent and Young Adults

Contraception counseling should aim to be gender affirming, patient goal oriented, and limit provider bias (A. Bonnington, et al., 2020, J.L. Manzer, A.V. Bell, 2021). Specifically, for TGD AYA, it is important to determine a thorough surgical and menstrual history that will inform contraceptive needs. In addition, the clinician should understand the patient’s goals of contraception. This could include possible prevention of pregnancy (exposure to sperm and ability to become pregnant), reduction in gender dysphoria related to menses, achieving amenorrhea to avoid menstrual care in public restrooms, treatment for breakthrough bleeding on testosterone therapy, or for another patient desired reason. By assessing the patient’s goals, the clinician will be able to better counsel and provide patient-oriented options.

It is important to assess medical history for any absolute or relative contraindications to contraceptive methods. The Centers for Disease Control and Prevention (CDC) Medical Eligibility Criteria (MEC) provides an overview of the impact of potential diseases on contraception choice (K. Curtis, et al., 2016). It is also important to inquire about medical problems that could impact disease severity or increase the risk of side effects. For example in lupus, estrogen containing contraceptives are contraindicated if positive antiphospholipid testing is noted (D.S. Reddy, 2017, ACOG, 2020).

Currently, there is no clear consensus on the effect of contraception on mental health diagnoses. Large datasets in the broader population have shown increased rates of depression and even suicidality (C.W. Skovlund, et al., 2016, S. Zettermark, et al., 2018, M.E. Newcomb, et al., 2020). However, while TGD AYA are at higher risk of mental health disorders such as depression, anxiety, and suicidal ideation (IOM, 2011, Connolly, et al., 2016), this must also be balanced with the benefits of menstrual suppression and pregnancy prevention and should not be considered a barrier to desired contraceptive care.

Contraceptive Options

There are two major categories of contraceptives: (1) hormonal and (2) non-hormonal. To help facilitate shared decision making with TGD AYA patients and their clinicians we have summarized potentially relevant factors relating to contraception in Figure 1.

Figure 1: Shared Decision-Making Contraceptive Options for Transgender and Gender Diverse Adolescent and Young Adults.

Figure 1:

Figure 1:

Figure 1:

Open in a new tab

A clinical patient-oriented table to utilize when discussing contraception options with transgender and gender diverse adolescent and young adults

There are no absolute contraindications to any form of contraception for TGD AYA. Some TGD individuals have reported preferring non-hormonal forms of contraception as both estrogen and progestin are considered “female” hormones (D. Boudreau, R. Mukerjee, 2019). In our experience, progesterone therapy is more often accepted especially given the availability of methods that have very low systemic hormone levels such as the hormonal intra-uterine device (IUD). While hormonal contraception with estrogen is often not prescribed given concern for utilizing a “feminizing” hormone and possible contribution to gender dysphoria, it is unlikely to have significant physical effects such as breast growth or reversal of masculining effects (D. Boudreau, R. Mukerjee, 2019, C. Krempasky, et al., 2020). A 2019 cross-sectional study (PRIDE study) notes younger participants (19–24 years old) and those who want to avoid estrogen therapy are more interested in over-the-counter progestin-only pill usage (Grindlay, et al., 2024). Another consideration is a theoretical increased risk for VTE events in patients on testosterone compared to cisgender females, but there is no clear clinical data to support this speculation (D. Boudreau, R. Mukerjee, 2019, M. Oakes, et al., 2021).

Hormonal Contraception Options

Hormonal contraception options can contain both estrogen and progestin or progestin only methods.

Estrogen & Progestin Options:

These options include two steroid-based sex hormones, estrogen (most often ethinyl estradiol) and progestin (synthetic progesterone with many available types). The method of delivery includes a pill taken daily, a patch placed weekly, or a ring placed vaginally monthly. When the combined oral contraceptive pill was initially designed by John Rock in the 1950’s, it was given cyclically with seven days of a placebo which led to a progestin withdrawal bleed to mimic typical menses and improve acceptability. Skipping this hormone free interval or continuous use of the hormonal method can lead to fewer menstruating days annually and is often preferred by TGD youth (A. Edelman, et al., 2005). In this approach, the method is continued until bothersome breakthrough bleeding occurs at which time the patient is counseled to skip the methods for 4 days to allow for a full withdrawal bleed. This strategy of extended cycling (allowing for withdrawal bleeding every 2–3 months) or continuous cycling (no withdrawal bleed) can be utilized for the patch and ring as well.

Progestin Only Options:

These contraceptive methods include a variety of different options with varying routes of use, dosing, and types of progestin. There are progestin only daily pills (POPs including norethindrone or drospirenone), every three-month intramuscular injection (e.g., medroxyprogesterone acetate), arm implant (e.g., etonogestrel implant), or intrauterine device (e.g., levonorgestrel IUD). Pregnancy prevention efficacy varies, but overall progestin only methods are very effective with the progestin-only pill at 93% to the etonogestrel implant at 99.95% with typical use (L.E. Britton, et al., 2020).

These methods are associated with varying rates of breakthrough bleeding which can be bothersome to patients (implant ~25–40%, IUD, ~39% spotting first 3 months of insertion, see Figure 1 for amenorrhea rates) (D. Mansour, et al., 2019, L.Y. Maldonado, et al., 2020). In the above stated retrospective study of TGD AYA individuals, the amenorrhea rate at 1 year was 89% with the levonorgestrel IUD (B. Schwartz et al., 2023). This amenorrhea rate did not differentiate between those on testosterone therapy. An additional retrospective study in TGD noted an amenorrhea rate of 50% for those with placement of IUD after breakthrough bleeding on testosterone therapy, but the sample size was limited (Grimstad et al., 2024). Larger, prospective studies are needed to help better counsel patients about amenorrhea and breakthrough bleeding management.

An additional consideration is that IUD insertion can be very uncomfortable both emotionally and physically (possibly secondary to gender dysphoria, genital atrophy secondary to testosterone therapy, or differences in sexual practices). For young never sexually active TGD individuals or those desiring more pain management, IUD insertion can be performed under sedation or anesthesia in the operating room. For those interested in office placement, the provider should discuss pain management modalities and utilize trauma informed care for all pelvic exams and procedures.

Non-Hormonal Options

For non-hormonal contraception, there are both reversible and irreversible options.

Reversible:

These methods include as needed barrier methods such as external and internal condom, diaphragm, spermicide, and cervical cap. These methods are utilized at time of sexual encounter. Condoms are the only method that provide the additional benefit of preventing STI transmission. A copper IUD is also a non-permanent non-hormonal option with high efficacy but has a side effect profile of heavy menstrual bleeding and dysmenorrhea (G. Farr, R Amayta, 1994). Some copper IUD data suggests that these intermenstrual side effects (bleeding and pain) do decrease over 12-month use (D. Hubacher, et al., 2009).

Irreversible:

Sterilization or permanent contraception involves surgical intervention to damage or remove reproductive structures to prevent pregnancy. They are considered non-reversible and include bilateral tubal ligation or salpingectomy, hysterectomy, and/or bilateral oophorectomy. As these options may be an important part of a TGD person’s journey or necessary prior to other surgical interventions, they may be offered in patients who are of the age of majority and who desire this surgical intervention. We also would consider the involvement of a specialized gender mental health care provider when counseling or offering gender affirming surgical interventions to AYA (S.E. James, et al., 2015, C.A. Ferrando, 2024).

Emergency Contraception

There are also varying forms of emergency contraception (EC) or contraception that can be utilized after unprotected intercourse or exposure to sperm has taken place. TGD AYA can utilize hormonal options including the levonorgestrel IUD, oral levonorgestrel, or oral ulipristal acetate and there are no contraindications to these methods (Salcedo, et al., 2023). Both the copper and levonorgestrel IUD is effective in preventing pregnancy if inserted within 5 days of intercourse (Salcedo, et al., 2023).

Oral levonorgestrel and ulipristal acetate work within 96 hours and 120 hours respectively after unprotected sex by preventing or delaying ovulation. There may be additional barriers to use of emergency contraception in TGD individuals such as access to a gender inclusive gynecologist within a short time frame of unprotected sex or fear or inability to access behind the counter medications given gender expression. Providers of TGD AYA who may have unprotected sex can consider discussing a prescription of oral EC prior to unprotected sex to help alleviate these barriers. Additionally, they can provide counseling and guidance about same day or next day delivery through a variety of different online prescribers (Salcedo, et al., 2023).

Contraception Considerations Specific to Transgender and Gender Diverse Adolescent and Young Adults

Preventing Pregnancy & Assessing Future Fertility Goals

Any person who can become pregnant should be counseled regarding fertility goals. If they do not want to be pregnant, contraception counseling utilizing the CDC’s MEC criteria and a knowledge of gender affirming care is critical (K.M. Curtis, et al., 2016). There are multiple studies showing that both patients and clinicians believe that TGD patients on testosterone who are amenorrheic are not able to become pregnant (A. Gomez, et al., 2016, L. Abern, K. Maguire, 2018, A. Light, et al., 2018, C. Krempasky, et al., 2020).

Depending on data utilized, approximately 16–31% of TGD adults believe that testosterone is a form of contraception (A. Light, et al., 2018, C. Krempasky, et al., 2020). One small, mixed methods study of AFAB individuals who experienced pregnancy after transition (with a mean age of 25 years old) noted that patients on testosterone were less likely to report hormonal contraceptive use compared to those not on testosterone; however, exposure to sperm during contraception use was not clearly defined (A.D. Light, 2014). That same study found that 20% of participants became pregnant while amenorrheic. While there is likely suppression of the hypothalamic pituitary ovarian axis with exogenous testosterone use, and testosterone leads to at least partial endometrial quiescence, one study demonstrates that up to one-third of TGD on testosterone ovulate (J.D. Asseler, et al., 2024). Additionally, there is limited data looking at abortion in this population. However, a large, sampled survey of young TGD adults less than 30 years old found that among those who experienced a pregnancy, 21% had an abortion (H. Moseson, et al., 2021). This underlines the continued importance of contraception counseling in this population. TGD AYA patients can become pregnant while amenorrheic and on testosterone therapy and there is a continued need to assess fertility goals within this population.

Puberty Suppression & Ovulation

Some patients and families opt to initiate a GnRH (gonadotrophin releasing hormone) agonist to stop the progression of puberty at Tanner stage 2 and prior to menarche. There is evidence that the gonadotropins are suppressed similarly in TGD AYA patients as to patients with precocious puberty (J.D. Mejia-Otero, et al., 2021). There are reported cases of unintended pregnancy after administration of GnRH agonists for patients with infertility and endometriosis (H. Wu, et al., 2021), thus it should not be considered a form of contraception. Furthermore, when there is a discussion of testosterone hormone therapy, it is important to reinitiate a conversation about sexual activity, pregnancy potential, fertility goals, and contraception use.

Considerations regarding future pregnancy desire and fertility counseling

Although a TGD AYA patient may request contraception, they may be interested in future fertility. The Endocrine Society Guidelines and WPATH both recommend that TGD individuals be counselled about the possible effects of gender affirming hormone therapy on future fertility. The contraceptive visit may be an ideal time to discuss family planning wishes, effects of gender affirming therapy, and possible fertility preservation options (E. Coleman, A.E. Radix, et al., 2022). Unfortunately, there are no large, prospective studies assessing the long-term effect of testosterone use on ovarian reserve and reproductive potential. Smaller studies have confirmed that there is a resumption of menses after discontinuing testosterone therapy and there are also reports of patients becoming pregnant without resumption of menses (A.D. Light, 2014). Several case series report successful ovulation induction in individuals who achieved menarche and subsequently were treated with testosterone.

The effect of GnRH agonists followed by testosterone on fertility is unknown. There are a few case reports of successful ovarian stimulation success following GnRH agonists, but there is no published outcomes data for ovulation induction in those who received testosterone therapy following GnRH agonists (A. Ghofranian, et al., 2023, M. Slonim, et al., 2023). As clinicians, it is important to discuss future fertility interests and goals, limitations in current data, and assessment of pregnancy potential. When a patient expresses a desire for future fertility, they should be referred to a fertility specialist and offered fertility preservation options.

Achieving Amenorrhea & Menstrual Suppression

As mentioned above, one reason that a TGD AYA may seek contraceptive care is to achieve amenorrhea, lighten menstrual bleeding, or minimize menstrual symptoms. This could be due to several different reasons such as primary dysmenorrhea, endometriosis, heavy menstrual bleeding, polycystic ovarian syndrome, or gender dysphoria. There is an association between chronic pelvic pain and initiation of testosterone therapy most notably in the first six months and perhaps secondary to uterine contractions or pelvic floor dysregulation (S. Zwickl, et al., 2023). There is also a unique need or concern in this population to avoid heavy or regular menstrual bleeding due to considerations of harm or harassment about menstrual care in public restrooms (J. Chrisler, et al., 2016).

There are multiple studies suggesting that rates of amenorrhea in TGD persons on testosterone is high but variable (55–96% at 6 months dependent on the referenced study) (A. Nakamura, et al., 2013, S. Ahmad, et al., 2017). Furthermore, despite high rates of amenorrhea, there is also a high rate (25–27%) of breakthrough bleeding in these patients two years after initiation of therapy (J. Defreyne, et al., 2020, F. Grimstad, et al., 2021). A recent study in 2024 by Grimstad et al. reports amenorrhea rates for TGD on testosterone therapy and rates of amenorrhea after initiating varying options for menstrual suppression, ensuring compliance with testosterone therapy, changing testosterone formulation, and discontinuing current menstrual suppression method (Grimstad, et al., 2024). Given this, it is important for clinicians caring for TGD AYA on testosterone therapy to discuss role of contraceptives in achieving amenorrhea or treating breakthrough bleeding (J. Defreyne, et al., 2020, F. Grimstad, et al., 2024).

Protecting the Endometrial Lining

Testosterone is peripherally aromatized to estrogen and is often associated with anovulation and lack of progesterone, and thus, some have speculated that testosterone may be associated with endometrial hyperplasia over the long term (M. Hawkins, et al., 2021). Androgen receptors on the endometrium play a key role in the late luteal phase and decidualization in the event of pregnancy (I. Simitsidellis, et al., 2018). Data suggests that the endometrium remains active in 40–69% of patients on testosterone therapy despite often being amenorrheic (H.P. Crissman, et al., 2021, F. Grimstad, et al., 2021, M. Hawkins, et al., 2021). Other studies dispute this finding and have noted that the endometrium is in fact inactive in those on testosterone therapy (A.M. Perrone, et al., 2009). Hormonal contraception containing progesterone is known to protect against endometrial hyperplasia/cancer and may reassure the provider and patient of endometrial protection especially for those on long term testosterone use and are not planning hysterectomy (L.K. Nees, et al., 2022, S. Uccella, et al., 2022). Given this conflicting data and lack of long-term studies, there is no current recommendation for endometrial protection in patients who are on testosterone therapy.

Conclusions

There continues to be a need to assess contraception use and preferences in TGD adolescent and young adults. TGD AYA patients may seek contraception care that is discrete, avoids estrogen, helps alleviate gender dysphoria, and potentially leads to amenorrhea. Given the paucity of national data and lack of inclusion of gender identity on large, sampled data sets, most data in this population comes from smaller, cohort or convenient sampling techniques. While still informative, it is critical for us to better understand this population’s needs. Furthermore, many of the studies focusing on TGD patients are predominantly in white and higher socioeconomic status (SES) individuals and not encompassing the intersectionality appreciated with TGD persons of color or lower SES. Future studies could include larger cohorts and continued qualitative studies among TGD AYA that may help better inform providers of TGD AYA and aid in contraception counseling.

Funding:

Last author supported by NIH Z1A HD008985

Footnotes

Declaration of Interest: The authors have no conflict of interests to report. Please see funding note below.

References

  1. 2020. Gynecologic Management Of Adolescents And Young Women With Seizure Disorders. Acog Committee Opinion No. 806. 409 12th Street Sw, Washington, Dc 20024–2188: American College Of Obstetricians And Gynecologists [Google Scholar]
  2. Abern L & Maguire K 2018. Contraception Knowledge In Transgender Individuals: Are We Doing Enough? Obstetrics And Gynecology, 131, 66s–66s. [Google Scholar]
  3. Agénor M, Cottrill AA, Kay E, Janiak E, Gordon AR & Potter J 2020. Contraceptive Beliefs, Decision Making And Care Experiences Among Transmasculine Young Adults: A Qualitative Analysis. Perspect Sex Reprod Health, 52, 7–14. [DOI] [PubMed] [Google Scholar]
  4. Ahmad S & Leinung M 2017. The Response Of The Menstrual Cycle To Initiation Of Hormonal Therapy In Transgender Men. Transgend Health, 2, 176–179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Asseler JD, Del Valle JS, Chuva De Sousa Lopes SM, Verhoeven MO, Goddijn M, Huirne JAF & Van Mello NM. 2024. One-Third Of Amenorrheic Transmasculine People On Testosterone Ovulate. Cell Rep Med, 101440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bonnington A, Dianat S, Kerns J, Hastings J, Hawkins M, De Haan G & Obedin-Maliver J 2020. Society Of Family Planning Clinical Recommendations: Contraceptive Counseling For Transgender And Gender Diverse People Who Were Female Sex Assigned At Birth. Contraception, 102, 70–82. [DOI] [PubMed] [Google Scholar]
  7. Boudreau D & Mukerjee R 2019. Contraception Care For Transmasculine Individuals On Testosterone Therapy. J Midwifery Womens Health, 64, 395–402. [DOI] [PubMed] [Google Scholar]
  8. Britton LE, Alspaugh A, Greene MZ & Mclemore MR 2020. Ce: An Evidence-Based Update On Contraception. Am J Nurs, 120, 22–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Buck E, Mcnally L, Jenkins SM Menstrual Suppression. [Updated 2023 May 24]. In: Statpearls. Treasure Island (Fl): Statpearls Publishing; 2024. Jan-. Available From: Https://Www.Ncbi.Nlm.Nih.Gov/Books/Nbk592411/ [PubMed] [Google Scholar]
  10. Chrisler JC, Gorman JA, Manion J, Murgo M, Barney A, Adams-Clark A, Newton JR & Mcgrath M 2016. Queer Periods: Attitudes Toward And Experiences With Menstruation In The Masculine Of Centre And Transgender Community. Cult Health Sex, 18, 1238–50. [DOI] [PubMed] [Google Scholar]
  11. Coleman E, Radix AE, Bouman WP, Brown GR, De Vries ALC, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, Hancock AB, Johnson TW, Karasic DH, Knudson GA, Leibowitz SF, Meyer-Bahlburg HFL, Monstrey SJ, Motmans J, Nahata L, Nieder TO, Reisner SL, Richards C, Schechter LS, Tangpricha V, Tishelman AC, Van Trotsenburg MAA, Winter S, Ducheny K, Adams NJ, Adrian TM, Allen LR, Azul D, Bagga H, Basar K, Bathory DS, Belinky JJ, Berg DR, Berli JU, Bluebond-Langner RO, Bouman MB, Bowers ML, Brassard PJ, Byrne J, Capitan L, Cargill CJ, Carswell JM, Chang SC, Chelvakumar G, Corneil T, Dalke KB, De Cuypere G, De Vries E, Den Heijer M, Devor AH, Dhejne C, D’marco A, Edmiston EK, Edwards-Leeper L, Ehrbar R, Ehrensaft D, Eisfeld J, Elaut E, Erickson-Schroth L, Feldman JL, Fisher AD, Garcia MM, Gijs L, Green SE, Hall BP, Hardy TLD, Irwig MS, Jacobs LA, Janssen AC, Johnson K, Klink DT, Kreukels BPC, Kuper LE, Kvach EJ, Malouf MA, Massey R, Mazur T, Mclachlan C, Morrison SD, Mosser SW, Neira PM, Nygren U, Oates JM, Obedin-Maliver J, Pagkalos G, Patton J, Phanuphak N, Rachlin K, Reed T, Rider GN, Ristori J, Robbins-Cherry S, Roberts SA, Rodriguez-Wallberg KA, Rosenthal SM, Sabir K, et al. 2022. Standards Of Care For The Health Of Transgender And Gender Diverse People, Version 8. Int J Transgend Health, 23, S1–S259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Connolly MD, Zervos MJ, Barone CJ 2nd, Johnsson CC & Joseph CL. 2016. The Mental Health Of Transgender Youth: Advances In Understanding. J Adolesc Health, 59, 489–495. [DOI] [PubMed] [Google Scholar]
  13. Crissman HP & Moravek MB 2021. Centering Patients: A Quest To Understand The Short- And Long-Term Implications Of Gender-Affirming Testosterone On The Endometrium. Fertil Steril, 115, 1181–1182. [DOI] [PubMed] [Google Scholar]
  14. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ & Whiteman MK 2016. U.S. Medical Eligibility Criteria For Contraceptive Use, 2016. Mmwr Recomm Rep, 65, 1–103. [DOI] [PubMed] [Google Scholar]
  15. Defreyne J, Vanwonterghem Y, Collet S, Iwamoto SJ, Wiepjes CM, Fisher AD, Schreiner T, Heijer MD & T’sjoen G 2020. Vaginal Bleeding And Spotting In Transgender Men After Initiation Of Testosterone Therapy: A Prospective Cohort Study (Enigi). Int J Transgend Health, 21, 163–175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF & Grimes DA 2005. Continuous Or Extended Cycle Vs. Cyclic Use Of Combined Oral Contraceptives For Contraception. Cochrane Database Syst Rev, Cd004695. [DOI] [PubMed] [Google Scholar]
  17. Farr G & Amatya R 1994. Contraceptive Efficacy Of The Copper T380a And The Multiload Cu250 Iud In Three Developing Countries. Adv Contracept, 10, 137–49. [DOI] [PubMed] [Google Scholar]
  18. Ferrando CA 2024. Gynecologic Care Of Transgender And Gender-Diverse People. Obstetrics And Gynecology, 243–255. [DOI] [PubMed] [Google Scholar]
  19. Ghofranian A, Estevez SL, Gellman C, Gounko D, Lee JA, Thornton K & Copperman AB 2023. Fertility Treatment Outcomes In Transgender Men With A History Of Testosterone Therapy. F S Rep, 4, 367–374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gomez A, Walters PC & Dao LT 2016. Testosterone In A Way Is Birth Control: Contraceptive Attitudes And Experiences Among Transmasculine And Genderqueer Young Adults. Contraception, 94, 422–423. [Google Scholar]
  21. Grimstad F, Kremen J, Shim J, Charlton BM & Boskey ER 2021. Breakthrough Bleeding In Transgender And Gender Diverse Adolescents And Young Adults On Long-Term Testosterone. J Pediatr Adolesc Gynecol, 34, 706–716. [DOI] [PubMed] [Google Scholar]
  22. Grimstad FW, Boskey ER, Clark RS, Ferrando CA, Management Of Breakthrough Bleeding In Transgender And Gender Diverse Individuals On Testosterone. Am J Obstet Gynecol. 2024. Jun 13:S0002–9378(24)00667–7. Doi: 10.1016/J.Ajog.2024.06.004. Epub Ahead Of Print. [DOI] [PubMed] [Google Scholar]
  23. Grindlay K, Obedin-Maliver J, Ragosta S, Hastings J, Lunn MR, Fentje A, Capriotti MR, Dastur Z, Lubensky ME, Moseson H (2024). “Interest In Over-The-Counter Progestin-Only Pills Among Transgender, Nonbinary, And Gender-Expansive Individuals In The United States.” Am J Obstet Gynecol 230(6): 657.E651–657.E617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hall KS & Trussell J 2012. Types Of Combined Oral Contraceptives Used By Us Women. Contraception, 86, 659–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hawkins M, Deutsch MB, Obedin-Maliver J, Stark B, Grubman J, Jacoby A & Jacoby VL 2021. Endometrial Findings Among Transgender And Gender Nonbinary People Using Testosterone At The Time Of Gender-Affirming Hysterectomy. Fertil Steril, 115, 1312–1317. [DOI] [PubMed] [Google Scholar]
  26. Hillard PA 2014. Menstrual Suppression: Current Perspectives. Int J Womens Health, 6, 631–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hubacher D, Chen PL & Park S 2009. Side Effects From The Copper Iud: Do They Decrease Over Time? Contraception, 79, 356–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Institute Of Medicine (Us) Committee On Lesbian, Bisexual G, And Transgender Health Issues And Research Gaps And Opportunities 2011. The Health Of Lesbian, Gay, Bisexual, And Transgender People, Washignton, Dc, National Academies Press (Us). [PubMed] [Google Scholar]
  29. James SE, Herman JL, Rankin S, Keisling M, Mottet L, & Anafi M 2016. The Report Of The 2015 U.S. Transgender Survey. Washington, Dc: National Center For Transgender Equality. [Google Scholar]
  30. Krempasky C, Harris M, Abern L & Grimstad F 2020. Contraception Across The Transmasculine Spectrum. Am J Obstet Gynecol, 222, 134–143. [DOI] [PubMed] [Google Scholar]
  31. Light AD, Obedin-Maliver J, Sevelius JM & Kerns JL 2014. Transgender Men Who Experienced Pregnancy After Female-To-Male Gender Transitioning. Obstet Gynecol, 124, 1120–1127. [DOI] [PubMed] [Google Scholar]
  32. Light A, Wang LF, Zeymo A & Gomez-Lobo V 2018. Family Planning And Contraception Use In Transgender Men. Contraception, 98, 266–269. [DOI] [PubMed] [Google Scholar]
  33. Maldonado LY, Sergison JE, Gao X & Hubacher D 2020. Menstrual Bleeding And Spotting With The Levonorgestrel Intrauterine System (52 Mg) During The First-Year After Insertion: A Systematic Review And Meta-Analysis. Am J Obstet Gynecol, 222, 451–468.E9. [DOI] [PubMed] [Google Scholar]
  34. Mansour D, Fraser IS, Edelman A, Vieira CS, Kaunitz AM, Korver T, Pong A, Lin J, Shah AK, Fox M, Rekers H & Creinin MD 2019. Can Initial Vaginal Bleeding Patterns In Etonogestrel Implant Users Predict Subsequent Bleeding In The First 2 Years Of Use? Contraception, 100, 264–268. [DOI] [PubMed] [Google Scholar]
  35. Manzer JL & Bell AV 2021. “We’re A Little Biased”: Medicine And The Management Of Bias Through The Case Of Contraception. Journal Of Health And Social Behavior, 62, 120–135. [DOI] [PubMed] [Google Scholar]
  36. Mejia-Otero JD, White P & Lopez X 2021. Effectiveness Of Puberty Suppression With Gonadotropin-Releasing Hormone Agonists In Transgender Youth. Transgend Health, 6, 31–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Miller L, Hughes Jp. Continuous Combination Oral Contraceptive Pills To Eliminate Withdrawal Bleeding: A Randomized Trial. Obstet Gynecol. 2003. Apr;101(4):653–61. Doi: 10.1016/S0029-7844(03)00014-0. Pmid: 12681866. [DOI] [PubMed] [Google Scholar]
  38. Moseson H, Fix L, Ragosta S, Forsberg H, Hastings J, Stoeffler A, Lunn MR, Flentje A, Capriotti MR, Lubensky ME & Obedin-Maliver J 2021. Abortion Experiences And Preferences Of Transgender, Nonbinary, And Gender-Expansive People In The United States. Am J Obstet Gynecol, 224, 376 E1–376 E11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moussaoui D, O’connell MA, Elder CV, Grover SR & Pang KC 2023. Characteristics Of Menstrual Suppression And Its Association With Mental Health In Transgender Adolescents. Obstet Gynecol, 142, 1096–1104. [DOI] [PubMed] [Google Scholar]
  40. Mukherjea M 1981. Depo-Provera: Clinical Evaluation. Contracept Deliv Syst, 2, 259–69. [PubMed] [Google Scholar]
  41. Nakamura A, Watanabe M, Sugimoto M, Sako T, Mahmood S, Kaku H, Nasu Y, Ishii K, Nagai A & Kumon H 2013. Dose-Response Analysis Of Testosterone Replacement Therapy In Patients With Female To Male Gender Identity Disorder. Endocr J, 60, 275–81. [DOI] [PubMed] [Google Scholar]
  42. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB & Wallwiener M 2022. Endometrial Hyperplasia As A Risk Factor Of Endometrial Cancer. Arch Gynecol Obstet, 306, 407–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Newcomb ME, Hill R, Buehler K, Ryan DT, Whitton SW & Mustanski B 2020. High Burden Of Mental Health Problems, Substance Use, Violence, And Related Psychosocial Factors In Transgender, Non-Binary, And Gender Diverse Youth And Young Adults. Arch Sex Behav, 49, 645–659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Oakes M, Arastu A, Kato C, Somers J, Holly HD, Elstrott BK, Dy GW, Kohs TCL, Patel RR, Mccarty OJT, Deloughery TG, Milano C, Raghunathan V & Shatzel JJ 2021. Erythrocytosis And Thromboembolic Events In Transgender Individuals Receiving Gender-Affirming Testosterone. Thromb Res, 207, 96–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C & Meriggiola MC 2009. Effect Of Long-Term Testosterone Administration On The Endometrium Of Female-To-Male (Ftm) Transsexuals. J Sex Med, 6, 3193–200. [DOI] [PubMed] [Google Scholar]
  46. Pradhan S & Gomez-Lobo V 2019. Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-Releasing Hormone Analogues And Testosterone: Menstrual Suppression In Special Adolescent Populations. J Pediatr Adolesc Gynecol, 32, S23–S29. [DOI] [PubMed] [Google Scholar]
  47. Reddy DS 2017. Do Oral Contraceptives Increase Epileptic Seizures? Expert Rev Neurother, 17, 129–134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Salcedo J, Cleland K, Bartz D & Thompson I 2023. Society Of Family Planning Clinical Recommendation: Emergency Contraception. Contraception, 121, 109958. [DOI] [PubMed] [Google Scholar]
  49. Schwartz BI, Bear B, Short VL & Kazak AE 2023. Outcomes Of Menstrual Management Use In Transgender And Gender-Diverse Adolescents. Obstet Gynecol, 141, 748–755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Simitsidellis I, Saunders PTK & Gibson DA 2018. Androgens And Endometrium: New Insights And New Targets. Mol Cell Endocrinol, 465, 48–60. [DOI] [PubMed] [Google Scholar]
  51. Skovlund CW, Mørch LS, Kessing LV & Lidegaard Ø 2016. Association Of Hormonal Contraception With Depression. Jama Psychiatry, 73, 1154–1162. [DOI] [PubMed] [Google Scholar]
  52. Slonim M, Peate M, Merigan K, Lantsberg D, Anderson RA, Stern K, Gook D & Jayasinghe Y 2023. Ovarian Stimulation And Oocyte Cryopreservation In Females And Transgender Males Aged 18 Years Or Less: A Systematic Review. Front Endocrinol (Lausanne), 14, 1146476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Stark B, Hughto JMW, Charlton BM, Deutsch MB, Potter J & Reisner SL 2019. The Contraceptive And Reproductive History And Planning Goals Of Trans-Masculine Adults: A Mixed-Methods Study. Contraception, 100, 468–473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Pj Sulak, Smith V, Coffee A, Witt I, Kuehl Al, Kuehl Tj. Frequency And Management Of Breakthrough Bleeding With Continuous Use Of The Transvaginal Contraceptive Ring: A Randomized Controlled Trial. Obstet Gynecol. 2008. Sep;112(3):563–71. Doi: 10.1097/Aog.0b013e3181842071. Pmid: 18757653. [DOI] [PubMed] [Google Scholar]
  55. Turban JL, King D, Li JJ & Keuroghlian AS 2021. Timing Of Social Transition For Transgender And Gender Diverse Youth, K-12 Harassment, And Adult Mental Health Outcomes. J Adolesc Health, 69, 991–998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Uccella S, Zorzato PC, Dababou S, Bosco M, Torella M, Braga A, Frigerio M, Gardella B, Cianci S, Laganà AS, Franchi MP & Garzon S 2022. Conservative Management Of Atypical Endometrial Hyperplasia And Early Endometrial Cancer In Childbearing Age Women. Medicina (Kaunas), 58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wu H, Xu X, Ma C, Zhou Y, Pei S, Geng H, He Y, Xu Q, Xu Y, He X, Zhou P, Wei Z, Xu X & Cao Y 2021. No Significant Long-Term Complications From Inadvertent Exposure To Gonadotropin-Releasing Hormone Agonist During Early Pregnancy In Mothers And Offspring: A Retrospective Analysis. Reprod Biol Endocrinol, 19, 46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Zettermark S, Perez Vicente R & Merlo J 2018. Hormonal Contraception Increases The Risk Of Psychotropic Drug Use In Adolescent Girls But Not In Adults: A Pharmacoepidemiological Study On 800 000 Swedish Women. Plos One, 13, E0194773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Zwickl S, Burchill L, Wong AFQ, Leemaqz SY, Cook T, Angus LM, Eshin K, Elder CV, Grover SR, Zajac JD & Cheung AS 2023. Pelvic Pain In Transgender People Using Testosterone Therapy. Lgbt Health, 10, 179–190. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES